A 42-year-old woman with stage IB2 cervical cancer (tumor 5 cm, confined to cervix) is being counseled about treatment. Which imaging or clinical finding would be the best discriminator to decide between primary chemoradiation versus primary surgery (radical hysterectomy with pelvic lymphadenectomy)?

## Treatment Selection in Stage IB Cervical Cancer: Role of Lymph Node Status ### Clinical Context Stage IB cervical cancer can be managed by either primary surgery (radical hysterectomy + pelvic lymphadenectomy) or concurrent chemoradiation, depending on patient factors and disease extent. The presence of pelvic lymph node metastases is the single most important discriminator that shifts management away from surgery toward chemoradiation. ### Key Decision Point **Key Point:** Pelvic lymph node involvement (even micrometastases) is a contraindication to primary surgery and mandates chemoradiation. If lymph nodes are negative on imaging, surgery becomes a viable option; if positive, chemoradiation is preferred. ### Treatment Selection Algorithm ```mermaid flowchart TD A[Stage IB Cervical Cancer]:::outcome --> B{Pelvic LN metastases?}:::decision B -->|Yes| C[Chemoradiation + Brachytherapy]:::action B -->|No| D{Patient factors & preference?}:::decision D -->|Fit, desires surgery| E[Radical Hysterectomy + PLND]:::action D -->|Medically unfit or prefers RT| F[Chemoradiation + Brachytherapy]:::action C --> G[Better outcomes with LN involvement]:::outcome E --> H[Equivalent outcomes if LN negative]:::outcome ``` ### Comparison: Surgery vs Chemoradiation in IB Disease | Factor | Radical Hysterectomy | Chemoradiation | | --- | --- | --- | | **Pelvic LN metastases** | Contraindication | Preferred | | **Tumor size <4 cm** | Good option | Also acceptable | | **Tumor size >4 cm** | Less favorable | Preferred | | **Patient age** | Fit, <60 years preferred | Any age if medically fit | | **Stromal invasion depth** | Not a discriminator | Not a discriminator | | **Histological grade** | Not a discriminator | Not a discriminator | ### Clinical Pearl **Clinical Pearl:** Lymph node status is the most powerful predictor of treatment failure and survival in early-stage cervical cancer. Even clinically occult pelvic node metastases (found at surgery or imaging) change the entire treatment paradigm and prognosis. This is why MRI or PET-CT staging is critical before committing to primary surgery. ### High-Yield Points **High-Yield:** - Pelvic lymph node metastases = chemoradiation mandatory - Negative pelvic nodes + patient fit = surgery is acceptable - Stromal invasion depth, grade, and age do NOT change the fundamental treatment choice - Concurrent cisplatin-based chemoradiation improves survival vs RT alone (Cochrane meta-analysis) ### Why This Matters Lymph node involvement carries a 2–3 fold increase in recurrence risk compared to node-negative disease. Patients with node-positive disease benefit from systemic chemotherapy (cisplatin) combined with radiotherapy, whereas node-negative patients can be adequately treated with surgery alone if fit. [cite:NCCN Cervical Cancer Guidelines 2023; Cochrane Systematic Review on Chemoradiation in Cervical Cancer]